Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability
暂无分享,去创建一个
[1] J. Bernstein,et al. Current and Emerging Management Options for Hereditary Angioedema in the US , 2012, Drugs.
[2] B. Zuraw. The Pathophysiology of Hereditary Angioedema , 2010, The World Allergy Organization journal.
[3] K. Wyrwich,et al. Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema , 2009, Quality of Life Research.
[4] M. Cicardi,et al. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. , 2009, Trends in molecular medicine.
[5] J. Bernstein,et al. Successful use of C1 inhibitor during mitral valve replacement surgery with cardiopulmonary bypass. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[6] B. Zuraw. Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new? , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[7] J. Bernstein. Hereditary angioedema: a current state-of-the-art review, VIII: current status of emerging therapies. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[8] A. Sheffer,et al. Hereditary angioedema: a current state-of-the-art review, V: attenuated androgens for the treatment of hereditary angioedema. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[9] Lynda Schneider,et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. , 2007, The Journal of allergy and clinical immunology.
[10] P. Schlattmann,et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). , 2007, The Journal of allergy and clinical immunology.
[11] T. Craig,et al. Fresh frozen plasma for the treatment of hereditary angioedema. , 2007, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[12] J. Levy,et al. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema , 2006, Expert opinion on investigational drugs.
[13] A. Lehmann. Ecallantide (Dyax/Genzyme). , 2006, Current opinion in investigational drugs.
[14] T. Caballero,et al. Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. , 2006, Journal of Allergy and Clinical Immunology.
[15] M. Gompels,et al. C1 inhibitor deficiency: diagnosis , 2005, Clinical and experimental dermatology.
[16] M. Gompels,et al. C1 inhibitor deficiency: consensus document , 2005, Clinical and experimental immunology.
[17] B. Zuraw. Current and future therapy for hereditary angioedema. , 2005, Clinical immunology.
[18] Anthony Williams,et al. DX-88 and HAE: a developmental perspective. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[19] M. Cicardi,et al. Local bradykinin generation in hereditary angioedema. , 1999, The Journal of allergy and clinical immunology.
[20] M. Cicardi,et al. Plasma bradykinin in angio-oedema , 1998, The Lancet.
[21] J. Atkinson,et al. Hereditary angioedema: the use of fresh frozen plasma for prophylaxis in patients undergoing oral surgery. , 1975, The Journal of allergy and clinical immunology.